Skip to main content

Table 1 Health state utilities used in the base case analysis

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Health state

Utility (95% CI)

Reference

PFS

0.771 (0.731–0.810)

20

PPS

0.612 (0.564–0.659)

20

Death

0

―

  1. I confidence interval, PFS progression-free survival, PPS post-progression survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us